Brief: Aprea Therapeutics Presents Primary Analysis From Phase 2 Trial Of Eprenetapopt + Azacitidine

Aprea Therapeutics

13/12/2021 13:25

Dec 13 (Reuters) - Aprea Therapeutics Inc  APRE.O :
    * APREA THERAPEUTICS PRESENTS PRIMARY ANALYSIS FROM PHASE 2
TRIAL
OF EPRENETAPOPT + AZACITIDINE FOR POST-TRANSPLANT MAINTENANCE
THERAPY IN TP53 MUTANT MDS AND AML AT THE 2021 AMERICAN SOCIETY
OF HEMATOLOGY (ASH) ANNUAL MEETING
    * APREA THERAPEUTICS INC - 60% RELAPSE FREE SURVIVAL AT 1
YEAR
POST-TRANSPLANT
    * APREA THERAPEUTICS INC - 79% OVERALL SURVIVAL AT 1 YEAR
POST-TRANSPLANT
    * APREA THERAPEUTICS INC - MEDIAN OVERALL SURVIVAL OF 20.6
MONTHS

Source text for Eikon:  ID:nGNX1wRkkY 
Further company coverage:  APRE.O 

 ((Reuters.Briefs@thomsonreuters.com;))